Eli Lilly reported Phase 3 results for retatrutide (a triple-agonist targeting GIP/GLP-1/glucagon receptors), showing dose-dependent weight loss up to 28% over 80 weeks in its Triumph-1 trial, with the company highlighting tolerability performance relative to placebo. The readout included a low-dose arm that achieved 19% average weight loss. Lilly enrolled 2,339 participants with obesity and a non-diabetic complication, randomizing patients to weekly 4 mg, 9 mg, 12 mg retatrutide, or placebo. Nearly 500 patients moved into an extension, with follow-up reported through 104 weeks for that subset. The company’s data reinforce retatrutide’s positioning ahead of regulatory submissions and place pressure on obesity rivals as competition intensifies around multi-receptor GLP-1/GIP strategies and next-generation candidates.